Shocking Your Nerves to Heal Your Skin: VNS and Inflammatory Skin Disease

Inflammatory skin diseases affect hundreds of millions of people worldwide, and the frontline treatments, from topical steroids to powerful biologics, carry real costs and risks. A review published in the journal Dermatology by William J. Nahm and colleagues proposes something different: stimulating the vagus nerve to reset the immune signaling that drives conditions like psoriasis, eczema, seborrheic dermatitis, and rosacea. The evidence is still early, but the mechanistic case is unusually coherent for an emerging therapy.

How the Vagus Nerve Acts as an Immune Dispatcher

The vagus nerve runs from the brainstem down through the chest and abdomen, and it is the primary highway of the parasympathetic nervous system. One of its lesser-known jobs is policing inflammation. When the brain detects a systemic inflammatory signal, efferent vagal fibers release acetylcholine into peripheral tissues. That acetylcholine binds to alpha-7 nicotinic acetylcholine receptors (α7nAChR) on macrophages and other immune cells, suppressing production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. The review refers to this circuit as the cholinergic anti-inflammatory pathway, and it functions something like a medical dispatcher: the brain receives the alarm, then sends a targeted signal to quiet the response.

When vagal tone is low, as it is in many chronic disease states, this brake system weakens. Sympathetic dominance takes over, and the result is a persistently pro-inflammatory environment. Nahm and colleagues frame this through a concept they call the Cutaneous Vagal Dysregulation Inflammatory Axis, which positions common inflammatory skin disorders as downstream consequences of that autonomic imbalance. Crucially, the skin itself has no direct vagal innervation, yet neuromodulation via the cholinergic pathway still reaches the skin indirectly, through circulating cytokines and systemic immune modulation.

Preclinical Evidence in Psoriasis and Atopic Dermatitis

The animal data are the strongest leg of this story so far. In murine models, both invasive and non-invasive vagus nerve stimulation (VNS) significantly attenuated inflammatory markers. Preclinical studies found that VNS reduces clinical inflammation and pro-inflammatory cytokines in models of psoriasis and atopic dermatitis, including measurable decreases in epidermal hyperplasia, a hallmark of psoriatic plaques. Vitiligo models showed similar attenuation. On the molecular side, VNS suppressed NF-kB nuclear translocation, a central step in cytokine gene activation, and activated STAT3, which is involved in tissue repair. It also modulated α7nAChR to increase Netrin-1 expression and synthesis of lipoxin A4, a molecule that actively resolves inflammation rather than merely suppressing it.

The review also notes that VNS can reset a dysregulated hypothalamic-pituitary-adrenal (HPA) axis, reduce C-reactive protein levels, and modulate macrophage phenotypes in inflamed tissue. These are not skin-specific effects, but they bear directly on the systemic inflammatory burden that drives flares in eczema and psoriasis.

Early Clinical Reports in Seborrheic Dermatitis and Rosacea

Human data in dermatology are sparse, but what exists is encouraging. Published case reports document notable improvement in seborrheic dermatitis and rosacea following transcutaneous VNS (tVNS), a non-invasive approach that delivers electrical stimulation through the skin, typically at the ear. In a separate randomized clinical trial of transcutaneous auricular VNS for erythematotelangiectatic rosacea, participants showed significant improvement in facial erythema, with benefits sustained at 24 weeks. VNS has also demonstrated efficacy in other autoimmune and inflammatory conditions well outside dermatology: a systematic review of twelve clinical trials in autoimmune conditions found consistent reductions in pro-inflammatory cytokine levels, including in psoriatic arthritis and systemic lupus erythematosus. Rheumatoid arthritis and inflammatory bowel disease have both seen published clinical benefit from VNS, which gives the dermatologic hypothesis more biological plausibility.

The appeal of non-invasive tVNS is practical as well as scientific. Invasive VNS requires surgical placement of electrodes on the left cervical vagus nerve, with the cost and procedural risk that implies. Transcutaneous devices are cheaper, carry far fewer side effects (mild tingling, temporary voice changes, and ear warmth are the most commonly reported), and produce none of the systemic side effects associated with long-term anti-inflammatory drug use.

Open Questions Around Long-Term Efficacy and Dosing

The review is candid about what remains unknown. Dermatology-specific VNS studies are still emerging, and the field has not yet established optimal stimulation parameters: frequency, pulse width, session duration, and placement all vary across studies. Non-invasive VNS faces regulatory challenges, patient compliance issues, and a critical need for longer-term safety data before it can move into routine clinical use. Published anti-inflammatory data for tVNS specifically are also relatively rare compared to the invasive form, which complicates extrapolating mouse results to human clinical practice.

There is also the question of patient selection. Higher vagal tone, measurable through heart rate variability (HRV), is associated with better stress resilience and stronger anti-inflammatory signaling. It follows that patients with demonstrably low vagal tone, or specific autonomic profiles, might respond better to VNS than others. No dermatology trial has yet stratified patients this way.

What Personalized Bioelectronic Skin Therapy Could Look Like

The Nahm review lands as a call for systematic clinical investigation rather than a treatment ready for prescription pads. But the trajectory is coherent. Researchers at the Feinstein Institutes have developed a novel VNS method that targets specific nerve fiber subtypes, aiming to enable more personalized and effective treatments with fewer side effects, which could eventually allow clinicians to tune stimulation to the inflammatory profile of a given patient's skin disease.

For now, the framework the review offers is its most durable contribution. Framing psoriasis, eczema, rosacea, and seborrheic dermatitis as conditions shaped partly by autonomic dysregulation, rather than purely as local skin pathology, opens a new therapeutic axis. If controlled trials confirm what the mouse models and early case reports suggest, VNS could become a meaningful adjunct for patients who cycle through biologics or struggle with drug side effects. That is still an if, but it is a better-supported if than it was even a few years ago.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• Funding source was not disclosed by the authors.
• Human clinical evidence is limited to case reports; no randomized controlled trials in dermatological conditions have been conducted.
• Most mechanistic data derive from mouse models, which may not translate directly to human inflammatory skin disease.
• The proposed 'Cutaneous Vagal Dysregulation Inflammatory Axis' framework is theoretical and has not been validated in prospective studies.

This is a narrative review synthesizing preclinical mouse studies and isolated clinical case reports on vagus nerve stimulation for inflammatory skin diseases. Human evidence is limited to uncontrolled case reports, meaning causation cannot be established and findings may not generalize. The proposed mechanistic framework has not been prospectively validated, and the review has not been independently replicated.

References

1. William J. Nahm, Vincent Falanga, Ki-Joong Kim, Eui Namgung, John Koo (2026). The Role of the Vagus Nerve and Its Stimulation in Modulating Inflammatory Skin Diseases and Other Dermatologic Conditions: From Mechanisms to Therapeutics. Dermatology. https://doi.org/10.1159/000552415
2. Neuromodulation in Inflammatory Skin Disease – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809758/
3. William J. Nahm, Ki‐Joong Kim, Eui Namgung, John Koo, Yunha Han, Vincent Falanga (2026). Vagus Nerve Stimulation Reduces Cutaneous Inflammation and Proinflammatory Cytokines in Murine Models of Psoriasis and Atopic Dermatitis. Experimental Dermatology. https://doi.org/10.1111/exd.70297
4. Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Erythematotelangiectatic Rosacea: A Randomized Clinical Trial. JAMA Network. https://jamanetwork.com/journals/jamadermatology/article-abstract/2810842
5. Lina E. Lombo, Jorman H. Tejada‐Perdomo, Jorge A. Ramos‐Castaneda, Ronald G. Garcia (2025). Vagus Nerve Stimulation in Autoimmune Conditions: A Systematic Review. ACR Open Rheumatology. https://doi.org/10.1002/acr2.70137
6. Fu-Jun Liu, Jing Wu, Li-Jun Gong, Hong-Shuai Yang, Huan Chen (2024). Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2024.1490300
7. Feinstein Institutes research finds new vagus nerve stimulation method targets specific fibers, shows promise for improving therapeutic efficacy. northwell.edu. https://www.northwell.edu/news/news-releases/feinstein-institutes-research-finds-new-vagus-nerve-stimulation-method-targets-specific-fibers-shows-promise-for-improving-therapeutic-efficacy